Costs and Investments
CEO Stephen O’Hara on cutting costs, protecting margins and the company’s investment in ProBiotix Health.
Focus on profitability: keeping only the markets where the company is profitable
Lower costs: Stephen expects a 70 to 80% reduction in selling costs in the first half of 2026, including closing China operations and moving to a distributor model in the US
R&D: focus moves to second-generation products, in particular SweetBiotix
ProBiotix Health (PBX): OptiBiotix is a major investor in PBX, which has been profitable since the start of 2026